In contrast to long bone osteosarcoma, mandibular osteosarcoma are highly heterogeneous and morphologically overlap with benign tumors, obscuring diagnosis and treatment selection. Molecular characterization is difficult due to the paucity of available specimens of this rare disease. We aimed to characterize the spectrum of mandibular osteosarcoma using immunohistochemistry and molecular techniques (quantitative polymerase chain reaction, sequencing) and compare them with benign fibro-osseous lesions. Forty-nine paraffinembedded mandible osteosarcoma tissue samples were collected retrospectively and compared with 10 fibrous dysplasia and 15 ossifying fibroma cases. These were analyzed for molecular markers thought to differ between the different diseases and subtypes: MDM2 (murine double-minute type-2) overexpression; GNAS (guanine nucleotide-binding protein/alpha subunit) mutations; and amplification of MDM2 and/or RASAL1 (RAS protein activator like-1). Five fibroblastic high-grade osteosarcoma subtypes showed MDM2 amplification, including two with a microscopic appearance of high-grade osteosarcoma with part low-grade osteosarcoma (differentiated/dedifferentiated osteosarcoma) and MDM2 overexpression. The other three contained a co-amplification of MDM2 and RASAL1, a signature also described for juvenile ossifying fibroma, with no overexpression of MDM2.
INTRODUCTION
Mandibular osteosarcoma (MOS) account for less than 10% of all osteosarcoma (OS) [1] and, in contrast to their non-head and neck counterparts, they are characterized by a later onset and a lower propensity for distant metastases. Most series of MOS cases are of limited statistical value for the molecular characterization of different mandibular subtypes due to their rarity and histological heterogeneity. Some maxillary OS have been linked with the overexpression and amplification of MDM2 (murine double-minute type 2) and CDK4 (cyclin-dependent kinase 4), and the overexpression of Ezrin (a membrane-cytoskeleton linker protein involved in metastases), but these are the only molecular characterization studies reported thus far and have provided no prognostic value [2] [3] [4] .
According to the WHO 2013 classification [5] , low-grade OS (LGOS) represent 5-7% of all OS and are characterized by a paucicellular stroma with fusiform cells exhibiting minor cytonuclear atypia and well-differentiated bone trabeculae. Their genomic profile includes the presence of episomal ring neochromosomes containing a high-level amplification of the 12q13-15 region harboring the MDM2 and CDK4 genes. In 10-36% of LGOS cases some dedifferentiation into high-grade OS (HGOS) can occur, such that areas of low-and highgrade tumor can coexist microscopically (defined here as HGOS with part LGOS, or differentiated/dedifferentiated OS). Compared to the LGOS part, the HGOS contingent is composed of cells with larger atypia and a more immature neoplastic osteoid production [5] .
Tumour necrosis may also be present. Amplification of the MDM2 and CDK4 genes is also preserved in the dedifferentiated form of OS and is not observed in benign fibro-osseous lesions, providing an important diagnostic tool and prognostic factor [6] . When the LGOS in biopsy or surgical resection specimens, the diagnosis of dedifferentiated OS may instead be made from its molecular signature [5, 6, 7] .
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 8 In terms of osteosarcoma subtypes, HGOS include primary and secondary conventional sub-types, telangiectatic and small cell OS [5] . MOS may morphologically overlap with benign tumors such as fibrous dysplasia and ossifying fibromas [1] . Fibrous dysplasia tumors exhibit immature irregularly-shaped curvilinear trabeculae of woven bone associated with bland fibroblastic cells exhibiting rare mitoses. The juvenile type of ossifying fibroma (JOF) may resemble osteoblastoma [9] . JOF contain fusiform and giant plurinucleated cells surrounded by immature peripheral osseous trabecular structures that are then surrounded by osteoblastic cells. Activating mutations in the GNAS (guanine nucleotide-binding protein/alpha subunit) gene occur in up to 50% of fibrous dysplasias [10;11] and occasionally in LGOS [12] but have not been identified in ossifying fibromas [11] . The amplification of chromosome 12 which harbors the MDM2 and RASAL1
(RAS protein activator like-1; telomeric to MDM2 on chromosome 12) genes has also been recently identified as a molecular diagnostic marker for ossifying fibromas (mostly of juvenile-type) and is associated with aggressive tumors [13] . Alterations to the RASAL1 and MDM2 genes have not been reported in OS, however in some fibrous dysplasias and ossifying fibromas MDM2 amplification has been reported without an accompanying overexpression of the MDM2 protein [6] .
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT 9 Due to the significant overlap in the morphological and molecular presentation of benign and malignant mandibular tumors, a more comprehensive molecular characterization is required and should have a significant prognostic and therapeutic impact. In this study we have characterized the spectrum of MOS using immunohistochemistry and molecular techniques (quantitative polymerase chain reaction: qPCR, sequencing) and compared these with benign fibro-osseous lesions to investigate whether MOS that are histologically different exhibit distinct molecular features. Pathologists (GFPO) who further selected blocks to be used for tissue microarrays (TMAs).
MATERIALS AND METHODS

Patient and tumor characteristics
TMAs (triplicate sampling) were performed as recommended by Kononen et al. [14] . Since fixation and decalcification protocols have altered over time (some samples were fixed in formol and some in picric acid), wherever possible tumor samples from different tumor blocks for a given patient were used to compensate for any potential differences due to fixation and decalcification methods.
The 49 tumors were reviewed by the GFPO and reclassified into three subtypes 
Immunohistochemistry
The Ki67 proliferation index and MDM2 immunostainings were performed. Vessels were stained to detect the presence of CD34. Preparations were dried for 1 hour at 58°C, then overnight at 37°C. Sections were deparaffinized with toluene and rehydrated in ethanol. They were then pretreated with the high pH target retrieval solution (DAKO, EnVision Flex, Denmark), and a heat-based antigen retrieval method was used before incubation. 
qPCR
qPCR was performed using a Light Cycler 480 (Roche, Boulogne, France) with 50 ng DNA using the Sybr Green I Master kit (Roche). The ALB gene was used as a reference. Primer sequences are given in Table 1 . PCR was carried out as follows: following 5 minutes at 95°C, 45 amplification cycles were run, each consisting of 10 seconds at 95°C, 10 seconds at 60°C and 10 seconds at 72°C. The relative amounts of MDM2 and RASAL1 were established as a ratio of the reference gene (ALB) using Light Cycler Relative Quantification software
GNAS mutations
GNAS mutations in patients were determined as previously described [11] . (Roche), as previously described [11] . HRM and allele-specific PCR positive findings were further sequenced using bidirectional Sanger sequencing.
RESULTS
Clinical and pathological findings
Of the 49 patients treated for MOS in this series, 28 were male and 21 were female ( Table 1 ). In general, the low-grade component resembled either a desmoid tumor, with areas of moderately atypical fibroblastic cells in a fibrous stroma, or areas of well-differentiated osteogenesis associated with moderately atypical fibroblastic cells (Figure 1 ). Seven other fibroblastic cases that were rich in giant cells (see Table 1 ) had fibroblastic areas resembling JOF (areas of immature osteogenesis interspersed with fibroblastic areas and giant cells) ( Figure 2 ).
Due to the low number of patients in each category, no significant prognostic correlations could be made.
MDM2 immunohistochemistry
Of the 49 cases, 36 were suitable for immunohistochemistry analysis. Thirteen cases were excluded since control CD34 and Ki67 immunostainings were negative and these samples were assumed to have inadequate tissue quality due to decalcification. All of the 25 benign fibro-osseous tumor samples had positive CD34 and Ki67 staining and all were negative for MDM2 overexpression. Three MOS cases showed nuclear MDM2 immunostaining ( Figure 3 and Table 3 ); these were all of fibroblastic subtype and differentiated/dedifferentiated OS was suspected. All other subtypes, including the seven giant cell fibroblastic OS cases, were also negative for MDM2 staining.
Molecular findings
Fifteen cases were suitable for molecular analysis based on the quantity and/or quality of their extracted DNA ( Table 2 ).
Amplification of MDM2 and RASAL1
Five cases showed MDM2 amplification by qPCR. These were fibroblastic osteosarcomas, and included two cases in which differentiated/dedifferentiated osteosarcoma
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ACCEPTED MANUSCRIPT 14 was observed microscopically. These two cases had also shown MDM2 overexpression by IHC analysis. Unfortunately qPCR could not be used in the third case exhibiting overexpressed MDM2 due to insufficient DNA quality. The other three cases showing MDM2 amplification by qPCR also contained an amplification of RASAL1, but did not have MDM2 overexpression. These three cases were of the giant cell-rich fibroblastic subtype, with areas mimicking JOF. There were four other giant cell-rich fibroblastic OS, all of which had no MDM2 overexpression. One was negative for MDM2 and RASAL1 amplification but molecular analyses could not be performed on the other three due to poor DNA quality.
GNAS mutations
Due to insufficient quality or quantity of the DNA extracted, 35 samples had inconclusive results regardless of the techniques used. However, GNAS mutations were not detected in the remaining 14 cases.
DISCUSSION
This study is the largest to date to compare high-grade MOS samples. We have shown that different subtypes of high-grade MOS (graded according to the WHO 2013 classification)
can be characterized based on their morphology, immunohistochemistry and molecular biology. This has important implications in terms of the prognosis and understanding of the pathobiology of the MOS spectrum. MOS are usually treated based on their grade [15, 16] , with recent data suggesting that complete resection with neoadjuvant chemotherapy gives the best outcome for HGOS while LGOS are better treated with surgery alone [2] . However, our results suggest that this strategy overlooks potentially different behaviors within a given HGOS subtype.
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT 15 According to the molecular criteria of the WHO 2013 classification, LGOS and its dedifferentiated contingent (HGOS with part LGOS) are characterized by the amplification of MDM2, whereas conventional HGOS are thought to harbor a complex genomic profile with no distinct molecular signature.
Recent studies have suggested that benign fibro-osseous tumors of the jaw exhibit specific molecular characteristics. JOF can harbor a RASAL1 and MDM2 amplification that is associated with a greater clinical aggressiveness [13] . In addition, in both its monostotic or polyostotic presentations, or when associated with McCune Albright syndrome, fibrous dysplasia is characterized by somatic mutations of GNAS located on chromosome 20q13.3. [11, 17] . However, GNAS mutations have not been reported in other benign fibro-osseous lesions. In LGOS, the presence of GNAS mutations is controversial [11, 12, 18] , but a recent study of 31 cases of LGOS (confirmed through molecular analysis), led by the French Group of Bone Tumor pathologists (GFPO), did not find any GNAS mutations in either LGOS or its dedifferentiated contingent, supporting the specificity of GNAS mutations to fibrous dysplasia [18] . In accordance with this [11, 18] , none of the 14 OS cases in our cohort with adequate DNA quality contained GNAS mutations.
Despite the heterogeneous fixation and decalcification methods used and the limitations of using tissue microarrays rather than slides, we were able to assess the diagnostic value of MDM2 overexpression, MDM2 gene amplification, GNAS mutations and RASAL1/MDM2 amplifications. MDM2 overexpression can also be confirmed by FISH or CGH array analysis [10, 11] , however qPCR is usually used for decalcified tissues since FISH is not usually interpretable.
Our results show that molecular biology, alongside immunochemistry and morphological examination, can distinguish between the three subtypes of HGOS.
ACCEPTED MANUSCRIPT 16 Two HGOS exhibited MDM2 overexpression by immunohistochemistry analysis and MDM2 amplification by qPCR. These two OS exhibited morphologically-distinct areas of low-grade and high-grade fibroblastic OS. The third case, which was morphologically similar to the other two, overexpressed MDM2 but qPCR could not be performed because the tissues were damaged due to fixation and/or decalcification. Thus, based on the molecular pathology guidelines of the WHO classification, these three OS cases were reclassified as differentiated/dedifferentiated OS (HGOS with part LGOS), which have a better prognosis than conventional HGOS with its complex genomic profile [14] . This large study shows that high-grade MOS can be divided into subtypes of distinct pathogenesis ( Table 4 ). This could potentially improve prognosis and guide therapies. In future, the use of non-decalcified tissues or other extraction procedures should improve DNA integrity and permit the use of techniques such as CGH arrays or NGS. This will further develop these unique results and will ultimately improve our understanding of the etiological molecular pathways involved in MOS. 
CONCLUSION
